ÂÜÀòÂÒÂ×

Kenneth Kaitin is a Professor at Tufts University School of Medicine and Senior Fellow at Tufts Center for the Study of Drug Development. He is also Advisory Professor at Shanghai Medical College at Fudan University and serves on the faculty of the European Center for Pharmaceutical Medicine at the University of Basel. Dr. Kaitin is internationally recognized for contributions to the fields of drug development policy and science. He consults, speaks, and writes on global trends in pharmaceutical development, and he has provided public testimony before the U.S. Congress. A former President of the Drug Information Association, Dr. Kaitin recently served as Editor-in-Chief of Expert Review of Clinical Pharmacology, and as a consultant to the U.S. Department of Defense on bioterror countermeasures. In 2011, he received the Dr. Louis M. Sherwood Award, granted by the Academy of Pharmaceutical Physicians and Investigators; in 2020 he was named Global Fellow in Medicines Development by the International Federation of Pharmaceutical Physicians, and in 2021 he received the Distinguished Achievement Award from the Sino-American Pharmaceutical Professionals Association (SAPA). Dr. Kaitin is a director on the boards of Curis, Inc. (NASDAQ: CRIS), Bio-Tree Systems, Inc., and QCDx. He earned his BS from Cornell University and MS and PhD in pharmacology from the University of Rochester.